Endodiabesity

The North West of England Endocrinology, Diabetes and Obesity Newsletter

  • Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 15 other followers

  • Search site

  • Calendar

    November 2016
    M T W T F S S
    « Oct   Jan »
     123456
    78910111213
    14151617181920
    21222324252627
    282930  
  • Categories

  • Comments

  • Advertisements

Semaglutide and CV Outcomes

Posted by Akheel Syed on 12 November, 2016

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375:1834-1844

In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide.

http://www.nejm.org/doi/full/10.1056/NEJMoa1607141

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s